APO Research
Talk to an analyst

APO RESEARCH · REPORT

Non-Invasive Prenatal Screening (NIPS)

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Non-Invasive Prenatal Screening (NIPS) Market Outlook and Growth Opportunities 2026

11 April 2026Not stated

Choose your research edition.

Industry ResearchNon-Invasive Prenatal Screening (NIPS) Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Non-Invasive Prenatal Screening (NIPS) Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Non-Invasive Prenatal Screening (NIPS) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Non-Invasive Prenatal Screening (NIPS) Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal Non-Invasive Prenatal Screening (NIPS) Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Non-Invasive Prenatal Screening (NIPS) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Non-Invasive Prenatal Screening (NIPS) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Non-Invasive Prenatal Screening (NIPS) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Non-Invasive Prenatal Screening (NIPS) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Non-Invasive Prenatal Screening (NIPS) market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Non-Invasive Prenatal Screening (NIPS) market include Revvity, Quest Diagnostics, MedGenome, Mayo Clinic Laboratories, SYNLAB, Veritas Genetics, GGA, Cordlife and BGI Genomics, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Non-Invasive Prenatal Screening (NIPS) market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Non-Invasive Prenatal Screening (NIPS) and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Non-Invasive Prenatal Screening (NIPS) revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Non-Invasive Prenatal Screening (NIPS) market.

Non-Invasive Prenatal Screening (NIPS) Segment by Company

Revvity

Quest Diagnostics

MedGenome

Mayo Clinic Laboratories

SYNLAB

Veritas Genetics

GGA

Cordlife

BGI Genomics

Berry Genomics

Annaroad

Genesky

Weihansi Biomedical Technology

Non-Invasive Prenatal Screening (NIPS) Segment by Type

Screening in Uncomplicated Pregnancies

Screening in High-Risk Pregnancies

Others

Non-Invasive Prenatal Screening (NIPS) Segment by Application

Public Hospitals

Private Hospitals

Non-Invasive Prenatal Screening (NIPS) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Non-Invasive Prenatal Screening (NIPS) status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Non-Invasive Prenatal Screening (NIPS) key companies, revenue, market share, and recent developments.

3. To split the Non-Invasive Prenatal Screening (NIPS) breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Non-Invasive Prenatal Screening (NIPS) market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Non-Invasive Prenatal Screening (NIPS) significant trends, drivers, influence factors in global and regions.

6. To analyze Non-Invasive Prenatal Screening (NIPS) competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non-Invasive Prenatal Screening (NIPS) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Non-Invasive Prenatal Screening (NIPS) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non-Invasive Prenatal Screening (NIPS).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Non-Invasive Prenatal Screening (NIPS) industry.

Chapter 3: Detailed analysis of Non-Invasive Prenatal Screening (NIPS) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Non-Invasive Prenatal Screening (NIPS) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Non-Invasive Prenatal Screening (NIPS) in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Non-Invasive Prenatal Screening (NIPS) Industry Trends Table 2. Non-Invasive Prenatal Screening (NIPS) Industry Drivers Table 3. Non-Invasive Prenatal Screening (NIPS) Industry Opportunities and Challenges Table 4. Non-Invasive Prenatal Screening (NIPS) Industry Restraints Table 5. Global Non-Invasive Prenatal Screening (NIPS) Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Non-Invasive Prenatal Screening (NIPS) Revenue Share by Company (2021-2026) Table 7. Global Non-Invasive Prenatal Screening (NIPS) Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Non-Invasive Prenatal Screening (NIPS) Key Company Manufacturing Base & Headquarters Table 9. Global Non-Invasive Prenatal Screening (NIPS) Company, Product Type & Application Table 10. Global Non-Invasive Prenatal Screening (NIPS) Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Non-Invasive Prenatal Screening (NIPS) by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Screening in Uncomplicated Pregnancies Table 15. Significant Companies of Screening in High-Risk Pregnancies Table 16. Significant Companies of Others Table 17. Global Non-Invasive Prenatal Screening (NIPS) Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Non-Invasive Prenatal Screening (NIPS) Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Non-Invasive Prenatal Screening (NIPS) Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type (2021-2026) Table 21. Global Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Public Hospitals Table 23. Significant Companies of Private Hospitals Table 24. Global Non-Invasive Prenatal Screening (NIPS) Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Non-Invasive Prenatal Screening (NIPS) Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Non-Invasive Prenatal Screening (NIPS) Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application (2021-2026) Table 28. Global Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application (2027-2032) Table 29. Global Non-Invasive Prenatal Screening (NIPS) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Non-Invasive Prenatal Screening (NIPS) Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Region (2021-2026) Table 32. Global Non-Invasive Prenatal Screening (NIPS) Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Region (2027-2032) Table 34. Global Non-Invasive Prenatal Screening (NIPS) Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Non-Invasive Prenatal Screening (NIPS) Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Non-Invasive Prenatal Screening (NIPS) Sales Value Market Share by Country (2021-2026) Table 37. Global Non-Invasive Prenatal Screening (NIPS) Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Non-Invasive Prenatal Screening (NIPS) Sales Value Market Share by Country (2027-2032) Table 39. Revvity Company Information Table 40. Revvity Business Overview Table 41. Revvity Non-Invasive Prenatal Screening (NIPS) Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Revvity Non-Invasive Prenatal Screening (NIPS) Product Portfolio Table 43. Revvity Recent Development Table 44. Quest Diagnostics Company Information Table 45. Quest Diagnostics Business Overview Table 46. Quest Diagnostics Non-Invasive Prenatal Screening (NIPS) Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Quest Diagnostics Non-Invasive Prenatal Screening (NIPS) Product Portfolio Table 48. Quest Diagnostics Recent Development Table 49. MedGenome Company Information Table 50. MedGenome Business Overview Table 51. MedGenome Non-Invasive Prenatal Screening (NIPS) Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. MedGenome Non-Invasive Prenatal Screening (NIPS) Product Portfolio Table 53. MedGenome Recent Development Table 54. Mayo Clinic Laboratories Company Information Table 55. Mayo Clinic Laboratories Business Overview Table 56. Mayo Clinic Laboratories Non-Invasive Prenatal Screening (NIPS) Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Mayo Clinic Laboratories Non-Invasive Prenatal Screening (NIPS) Product Portfolio Table 58. Mayo Clinic Laboratories Recent Development Table 59. SYNLAB Company Information Table 60. SYNLAB Business Overview Table 61. SYNLAB Non-Invasive Prenatal Screening (NIPS) Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. SYNLAB Non-Invasive Prenatal Screening (NIPS) Product Portfolio Table 63. SYNLAB Recent Development Table 64. Veritas Genetics Company Information Table 65. Veritas Genetics Business Overview Table 66. Veritas Genetics Non-Invasive Prenatal Screening (NIPS) Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Veritas Genetics Non-Invasive Prenatal Screening (NIPS) Product Portfolio Table 68. Veritas Genetics Recent Development Table 69. GGA Company Information Table 70. GGA Business Overview Table 71. GGA Non-Invasive Prenatal Screening (NIPS) Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. GGA Non-Invasive Prenatal Screening (NIPS) Product Portfolio Table 73. GGA Recent Development Table 74. Cordlife Company Information Table 75. Cordlife Business Overview Table 76. Cordlife Non-Invasive Prenatal Screening (NIPS) Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Cordlife Non-Invasive Prenatal Screening (NIPS) Product Portfolio Table 78. Cordlife Recent Development Table 79. BGI Genomics Company Information Table 80. BGI Genomics Business Overview Table 81. BGI Genomics Non-Invasive Prenatal Screening (NIPS) Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. BGI Genomics Non-Invasive Prenatal Screening (NIPS) Product Portfolio Table 83. BGI Genomics Recent Development Table 84. Berry Genomics Company Information Table 85. Berry Genomics Business Overview Table 86. Berry Genomics Non-Invasive Prenatal Screening (NIPS) Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Berry Genomics Non-Invasive Prenatal Screening (NIPS) Product Portfolio Table 88. Berry Genomics Recent Development Table 89. Annaroad Company Information Table 90. Annaroad Business Overview Table 91. Annaroad Non-Invasive Prenatal Screening (NIPS) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 92. Annaroad Non-Invasive Prenatal Screening (NIPS) Product Portfolio Table 93. Annaroad Recent Development Table 94. Genesky Company Information Table 95. Genesky Business Overview Table 96. Genesky Non-Invasive Prenatal Screening (NIPS) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 97. Genesky Non-Invasive Prenatal Screening (NIPS) Product Portfolio Table 98. Genesky Recent Development Table 99. Weihansi Biomedical Technology Company Information Table 100. Weihansi Biomedical Technology Business Overview Table 101. Weihansi Biomedical Technology Non-Invasive Prenatal Screening (NIPS) Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 102. Weihansi Biomedical Technology Non-Invasive Prenatal Screening (NIPS) Product Portfolio Table 103. Weihansi Biomedical Technology Recent Development Table 104. Research Programs/Design for This Report Table 105. Authors List of This Report Table 106. Secondary Sources Table 107. Primary Sources List of Figures Figure 1. Non-Invasive Prenatal Screening (NIPS) Product Image Figure 2. Global Non-Invasive Prenatal Screening (NIPS) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Non-Invasive Prenatal Screening (NIPS) Market Size (2021-2032) & (US$ Million) Figure 4. Global Non-Invasive Prenatal Screening (NIPS) Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Screening in Uncomplicated Pregnancies Image Figure 8. Screening in High-Risk Pregnancies Image Figure 9. Others Image Figure 10. Global Non-Invasive Prenatal Screening (NIPS) Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Non-Invasive Prenatal Screening (NIPS) Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type (2021-2032) Figure 13. Public Hospitals Image Figure 14. Private Hospitals Image Figure 15. Global Non-Invasive Prenatal Screening (NIPS) Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Non-Invasive Prenatal Screening (NIPS) Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application (2021-2032) Figure 18. Global Non-Invasive Prenatal Screening (NIPS) Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Non-Invasive Prenatal Screening (NIPS) Sales Value (2021-2032) & (US$ Million) Figure 21. North America Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Non-Invasive Prenatal Screening (NIPS) Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Non-Invasive Prenatal Screening (NIPS) Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Non-Invasive Prenatal Screening (NIPS) Sales Value (2021-2032) & (US$ Million) Figure 27. South America Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Non-Invasive Prenatal Screening (NIPS) Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Screening in Uncomplicated Pregnancies
  • Screening in High-Risk Pregnancies
  • Others
Applications
  • Public Hospitals
  • Private Hospitals
Companies covered
  • Revvity
  • Quest Diagnostics
  • MedGenome
  • Mayo Clinic Laboratories
  • SYNLAB
  • Veritas Genetics
  • GGA
  • Cordlife
  • BGI Genomics
  • Berry Genomics
  • Annaroad
  • Genesky
  • Weihansi Biomedical Technology

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Non-Invasive Prenatal Screening (NIPS) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Non-Invasive Prenatal Screening (NIPS) Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Non-Invasive Prenatal Screening (NIPS) Market Dynamics
  1. 2.1 Non-Invasive Prenatal Screening (NIPS) Industry Trends
  2. 2.2 Non-Invasive Prenatal Screening (NIPS) Industry Drivers
  3. 2.3 Non-Invasive Prenatal Screening (NIPS) Industry Opportunities and Challenges
  4. 2.4 Non-Invasive Prenatal Screening (NIPS) Industry Restraints
3 Non-Invasive Prenatal Screening (NIPS) Market by Company
  1. 3.1 Global Non-Invasive Prenatal Screening (NIPS) Company Revenue Ranking in 2025
  2. 3.2 Global Non-Invasive Prenatal Screening (NIPS) Revenue by Company (2021-2026)
  3. 3.3 Global Non-Invasive Prenatal Screening (NIPS) Company Ranking (2024-2026)
  4. 3.4 Global Non-Invasive Prenatal Screening (NIPS) Company Manufacturing Base and Headquarters
  5. 3.5 Global Non-Invasive Prenatal Screening (NIPS) Company Product Type and Application
  6. 3.6 Global Non-Invasive Prenatal Screening (NIPS) Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Non-Invasive Prenatal Screening (NIPS) Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Non-Invasive Prenatal Screening (NIPS) Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Non-Invasive Prenatal Screening (NIPS) Market by Type
  1. 4.1 Non-Invasive Prenatal Screening (NIPS) Type Introduction
  2. 4.1.1 Screening in Uncomplicated Pregnancies
  3. 4.1.2 Screening in High-Risk Pregnancies
  4. 4.1.3 Others
  5. 4.2 Global Non-Invasive Prenatal Screening (NIPS) Sales Value by Type
  6. 4.2.1 Global Non-Invasive Prenatal Screening (NIPS) Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Non-Invasive Prenatal Screening (NIPS) Sales Value by Type (2021-2032)
  8. 4.2.3 Global Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type (2021-2032)
5 Non-Invasive Prenatal Screening (NIPS) Market by Application
  1. 5.1 Non-Invasive Prenatal Screening (NIPS) Application Introduction
  2. 5.1.1 Public Hospitals
  3. 5.1.2 Private Hospitals
  4. 5.2 Global Non-Invasive Prenatal Screening (NIPS) Sales Value by Application
  5. 5.2.1 Global Non-Invasive Prenatal Screening (NIPS) Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Non-Invasive Prenatal Screening (NIPS) Sales Value by Application (2021-2032)
  7. 5.2.3 Global Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application (2021-2032)
6 Non-Invasive Prenatal Screening (NIPS) Regional Value Analysis
  1. 6.1 Global Non-Invasive Prenatal Screening (NIPS) Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Non-Invasive Prenatal Screening (NIPS) Sales Value by Region (2021-2032)
  3. 6.2.1 Global Non-Invasive Prenatal Screening (NIPS) Sales Value by Region: 2021-2026
  4. 6.2.2 Global Non-Invasive Prenatal Screening (NIPS) Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Non-Invasive Prenatal Screening (NIPS) Sales Value (2021-2032)
  7. 6.3.2 North America Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Non-Invasive Prenatal Screening (NIPS) Sales Value (2021-2032)
  10. 6.4.2 Europe Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Non-Invasive Prenatal Screening (NIPS) Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Non-Invasive Prenatal Screening (NIPS) Sales Value (2021-2032)
  16. 6.6.2 South America Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Non-Invasive Prenatal Screening (NIPS) Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Country, 2025 VS 2032
7 Non-Invasive Prenatal Screening (NIPS) Country-level Value Analysis
  1. 7.1 Global Non-Invasive Prenatal Screening (NIPS) Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Non-Invasive Prenatal Screening (NIPS) Sales Value by Country (2021-2032)
  3. 7.2.1 Global Non-Invasive Prenatal Screening (NIPS) Sales Value by Country (2021-2026)
  4. 7.2.2 Global Non-Invasive Prenatal Screening (NIPS) Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Non-Invasive Prenatal Screening (NIPS) Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Non-Invasive Prenatal Screening (NIPS) Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Revvity
  2. 8.1.1 Revvity Company Information
  3. 8.1.2 Revvity Business Overview
  4. 8.1.3 Revvity Non-Invasive Prenatal Screening (NIPS) Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Revvity Non-Invasive Prenatal Screening (NIPS) Product Portfolio
  6. 8.1.5 Revvity Recent Developments
  7. 8.2 Quest Diagnostics
  8. 8.2.1 Quest Diagnostics Company Information
  9. 8.2.2 Quest Diagnostics Business Overview
  10. 8.2.3 Quest Diagnostics Non-Invasive Prenatal Screening (NIPS) Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Quest Diagnostics Non-Invasive Prenatal Screening (NIPS) Product Portfolio
  12. 8.2.5 Quest Diagnostics Recent Developments
  13. 8.3 MedGenome
  14. 8.3.1 MedGenome Company Information
  15. 8.3.2 MedGenome Business Overview
  16. 8.3.3 MedGenome Non-Invasive Prenatal Screening (NIPS) Revenue and Gross Margin (2021-2026)
  17. 8.3.4 MedGenome Non-Invasive Prenatal Screening (NIPS) Product Portfolio
  18. 8.3.5 MedGenome Recent Developments
  19. 8.4 Mayo Clinic Laboratories
  20. 8.4.1 Mayo Clinic Laboratories Company Information
  21. 8.4.2 Mayo Clinic Laboratories Business Overview
  22. 8.4.3 Mayo Clinic Laboratories Non-Invasive Prenatal Screening (NIPS) Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Mayo Clinic Laboratories Non-Invasive Prenatal Screening (NIPS) Product Portfolio
  24. 8.4.5 Mayo Clinic Laboratories Recent Developments
  25. 8.5 SYNLAB
  26. 8.5.1 SYNLAB Company Information
  27. 8.5.2 SYNLAB Business Overview
  28. 8.5.3 SYNLAB Non-Invasive Prenatal Screening (NIPS) Revenue and Gross Margin (2021-2026)
  29. 8.5.4 SYNLAB Non-Invasive Prenatal Screening (NIPS) Product Portfolio
  30. 8.5.5 SYNLAB Recent Developments
  31. 8.6 Veritas Genetics
  32. 8.6.1 Veritas Genetics Company Information
  33. 8.6.2 Veritas Genetics Business Overview
  34. 8.6.3 Veritas Genetics Non-Invasive Prenatal Screening (NIPS) Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Veritas Genetics Non-Invasive Prenatal Screening (NIPS) Product Portfolio
  36. 8.6.5 Veritas Genetics Recent Developments
  37. 8.7 GGA
  38. 8.7.1 GGA Company Information
  39. 8.7.2 GGA Business Overview
  40. 8.7.3 GGA Non-Invasive Prenatal Screening (NIPS) Revenue and Gross Margin (2021-2026)
  41. 8.7.4 GGA Non-Invasive Prenatal Screening (NIPS) Product Portfolio
  42. 8.7.5 GGA Recent Developments
  43. 8.8 Cordlife
  44. 8.8.1 Cordlife Company Information
  45. 8.8.2 Cordlife Business Overview
  46. 8.8.3 Cordlife Non-Invasive Prenatal Screening (NIPS) Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Cordlife Non-Invasive Prenatal Screening (NIPS) Product Portfolio
  48. 8.8.5 Cordlife Recent Developments
  49. 8.9 BGI Genomics
  50. 8.9.1 BGI Genomics Company Information
  51. 8.9.2 BGI Genomics Business Overview
  52. 8.9.3 BGI Genomics Non-Invasive Prenatal Screening (NIPS) Revenue and Gross Margin (2021-2026)
  53. 8.9.4 BGI Genomics Non-Invasive Prenatal Screening (NIPS) Product Portfolio
  54. 8.9.5 BGI Genomics Recent Developments
  55. 8.10 Berry Genomics
  56. 8.10.1 Berry Genomics Company Information
  57. 8.10.2 Berry Genomics Business Overview
  58. 8.10.3 Berry Genomics Non-Invasive Prenatal Screening (NIPS) Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Berry Genomics Non-Invasive Prenatal Screening (NIPS) Product Portfolio
  60. 8.10.5 Berry Genomics Recent Developments
  61. 8.11 Annaroad
  62. 8.11.1 Annaroad Company Information
  63. 8.11.2 Annaroad Business Overview
  64. 8.11.3 Annaroad Non-Invasive Prenatal Screening (NIPS) Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Annaroad Non-Invasive Prenatal Screening (NIPS) Product Portfolio
  66. 8.11.5 Annaroad Recent Developments
  67. 8.12 Genesky
  68. 8.12.1 Genesky Company Information
  69. 8.12.2 Genesky Business Overview
  70. 8.12.3 Genesky Non-Invasive Prenatal Screening (NIPS) Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Genesky Non-Invasive Prenatal Screening (NIPS) Product Portfolio
  72. 8.12.5 Genesky Recent Developments
  73. 8.13 Weihansi Biomedical Technology
  74. 8.13.1 Weihansi Biomedical Technology Company Information
  75. 8.13.2 Weihansi Biomedical Technology Business Overview
  76. 8.13.3 Weihansi Biomedical Technology Non-Invasive Prenatal Screening (NIPS) Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Weihansi Biomedical Technology Non-Invasive Prenatal Screening (NIPS) Product Portfolio
  78. 8.13.5 Weihansi Biomedical Technology Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst